U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06375109) titled 'PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC' on April 16.

Brief Summary: This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC.

Study Type: Interventional

Condition: Limited-stage Small-cell Lung Cancer

Intervention: * Drug: Tislelizumab